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Infective endocarditis is a relatively rare, but deadly cause of sepsis, with an overall
mortality ranging from 20 to 25% in most series. Although the classic clinical
classification into syndromes of acute or subacute endocarditis have not completely
lost their usefulness, current clinical forms have changed according to the profound
epidemiological changes observed in developed countries. In this review, we aim
to address the changing epidemiology of endocarditis, several recent advances in
the understanding of the pathophysiology of endocarditis and endocarditis-triggered
sepsis, new useful diagnostic tools as well as current concepts in the medical and
surgical management of this disease. Given its complexity, the management of infective
endocarditis requires the close collaboration of multidisciplinary endocarditis teams that
must decide on the diagnostic approach; the appropriate initial treatment in the critical
phase; the detection of patients needing surgery and the timing of this intervention; and
finally the accurate selection of patients for out-of-hospital treatment, either at home
hospitalization or with oral antibiotic treatment.
Keywords: infective endocarditis, transesophageal echocardiography - three-dimensional echocardiography,
positron - emission tomography, Staphycoccus aureus, viridans group streptococci, Enterococcus
INTRODUCTION
First described by the French physician Lazare Rivière more than 350 years ago, the
clinicopathological manifestations of the infection of heart valves were better characterized through
the enormous contributions of William Osler at the end of the 19th century (1). The infection
affects the endocardial surface of the heart, most commonly the valves, but also may occur on
mural endocardium, on cardiac septal defects, on arteriovenous or arterioarterial shunts and on
intravascular devices. The current name of this infection, infective endocarditis, was popularized in
the 1960s by Lerner and Weinstein to cover other possible, but infrequent etiologies in addition to
bacterial infections (2).
Although the incidence of infective endocarditis seems to be slightly increasing (3), this disease
continues to be a relatively rare, but severe cause of sepsis. Currently, up to 40–50% of affected
patients require valve surgery at some point during the clinical course, with overall mortality
remaining around 20–25% per year in most published series (4). Although the classic clinical
syndromes of acute or subacute endocarditis are still observed to a certain degree, current clinical
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forms have changed. Furthermore, there have been profound
epidemiological changes in high-income countries, with a clear
and progressive increase in the number of cases associated with
prosthetic valves and intravascular devices (3).
In this narrative review, we will address: (1) the
epidemiological changes mentioned above; (2) several new
advances in the understanding of the pathophysiology of
infective endocarditis and in endocarditis-triggered sepsis; (3)
new diagnostic tools; and finally (4) therapeutic aspects such as
the relevance of early surgical treatment in selected cases, new
available drugs and new useful treatment strategies.
The PubMed database was used to search medical literature
published in English from 1st January 2010 to 30th October
2020, using the search terms “infective endocarditis” AND
“epidemiology” OR “pathophysiology” OR “diagnosis” OR
“treatment” OR “management.” We reviewed both original and
review articles, excluding case reports and editorial articles. Some
earlier published articles were also included due to their relevance
to this review.
EPIDEMIOLOGY
Infective endocarditis is considered an infrequent disease, with
an annual incidence ranging from 1.5 to 15 cases per 100,000
inhabitants. It displays significant international variation (5, 6).
The highest rates have been found in the United States, while
the incidence is lower in Denmark. There is a significant lack
of epidemiological information from Asia, Oceania and Latin
America. Furthermore, the incidences can vary significantly
even within the same country (7). Even though the scarcity of
epidemiological data, particularly from low-income countries,
a slight increase in the incidence of infective endocarditis has
been noted since 2000. In this regard, controversy remains about
the true impact of restricting antibiotic prophylaxis in high-
risk patients, as recommended by NICE guidelines (8), with
some investigations showing an increasing trend of infective
endocarditis afterwards. The efficacy and impact of this strategy
on antibiotic resistance are yet to be fully addressed (9).
Toward a Nosocomial Profile of Infective
Endocarditis
A predisposing condition, such as rheumatic heart disease, is
nowadays less commonly detected among cases of infective
endocarditis, although the importance of such predisposing
conditions persists in low-income countries (10). Cases
associated with intravenous drug use have decreased globally,
but a dramatic increase of this habit continues to affect the
epidemiology of endocarditis in North America (11) and in
some Eastern European countries (12). Other risk factors
are being increasingly detected in high-income countries,
such as degenerative valve disease, intracardiac devices
(both cardiovascular implantable electronic devices as well
as left ventricular assist devices), indwelling catheters and
immunosuppression. This explains why the latest analyses
of the demographics of endocarditis cases show a trend
toward nosocomial characteristics in high-income countries:
older patients, staphylococcal (both Staphylococcus aureus and
coagulase-negative staphylococci) (13, 14) and enterococcal cases
(15), and the involvement of prosthetic valves and cardiovascular
implantable electronic devices (CIEDs) (3, 4, 11, 16, 17).
By contrast, the oral streptococcal (so-called “subacute”)
endocarditis classically associated with rheumatic heart disease
has become less frequent (5, 18).
Infrequent Etiologies and Culture-Negative
Endocarditis
Other etiologies of endocarditis are infrequent: 2–5% of cases
can be produced by Gram-negative bacilli (both aerobic Gram-
negative bacilli or by the known HACEK group: Haemophilus
spp., Aggregatibacter actinomycetemcomitans, Cardiobacterium
hominis, Eikenella corrodens, Kingella kingae). Also uncommon
are fungal endocarditis that can represent <2% of cases, mostly
produced by yeasts of the Candida spp. genus or rarely by other
yeasts or filamentous fungi.
Finally, a variable proportion (up to 10–20% of cases)
without documented etiology are considered “culture-negative
endocarditis,” mostly as a consequence of prior administration
of antibiotics or caused either by fastidious slow-growing
microorganisms or by truly non-cultivable intracellular bacteria
(e.g., Coxiella burnetii, Chlamydophila spp, Bartonella spp,
Tropheryma whippelii) (4, 19).
Infective Endocarditis Associated With
Transcatheter Aortic Valve Implantation
Transcatheter aortic valve implantation (TAVI) has led to a
revolution in the management of valvular heart disease. This
technique has become a suitable alternative to surgery in elderly
patients with aortic valve stenosis who carry a high or moderate
surgical risk (20). Therefore, the number of TAVI procedures
has dramatically increased in recent years (21). The incidence
of endocarditis associated with TAVI has been estimated to
be 0.8–1.4% (22, 23). A meta-analysis comparing endocarditis
following TAVI vs. surgical replacement found no difference
in the overall incidence (24). Endocarditis after TAVI displays
characteristics of healthcare-associated infections, with a high
predominance of staphylococcal and enterococcal infections (23,
25, 26). In-hospital mortality of TAVI-associated endocarditis is
elevated, strongly influenced by the epidemiological profile of the
patients (27).
Endocarditis and Sepsis
Sepsis and septic shock are severe complications that may arise
from any type of infection, with poor early and late prognoses
in the patients affected. A study on 894 episodes of infective
endocarditis showed that 17.4% of the patients had septic
shock at any time during hospitalization (28). A multivariate
analysis suggested that S. aureus and signs of a persistent
infection were independent predictors for the development of
septic shock, alongside a previous diagnosis of diabetes mellitus
and other systemic complications such as acute kidney injury
and supraventricular tachycardia. Furthermore, the multivariate
study indicated that the development of septic shock at any time
during hospitalization was strongly associated with in-hospital
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mortality. Similar results were obtained in a study comparing
endocarditis diagnosed “early” or “late” after the development
of first symptoms. That study showed that the so-called “acute
endocarditis” was more frequently presented as or complicated
with septic shock (29). Sepsis and septic shock are associated with
a 4-fold increase in the probability of death (28, 30).
Morbidity and Mortality
Despite advances in diagnosis and therapeutics, infective
endocarditis presents a significant morbidity burden and
a remarkably high overall mortality (20–25% of cases).
Endocarditis-related mortality has remained steadily high since
2000 and is strongly associated with several risk factors,
such as advanced age, a high Charlson comorbidity index,
non-community acquisition, prosthetic valves, staphylococcal
infections, perivalvular complications, stroke, and the non-
performance of surgery when indicated (3, 4, 11, 16, 31, 32).
Of note, studies on psychological outcomes in survivors after an
episode of endocarditis have demonstrated a reduction in quality
of life and the occurrence of posttraumatic stress disorder (33).
INFECTIVE ENDOCARDITIS
PATHOPHYSIOLOGY
The concurrence of several pathogenic events is required for the
development of infective endocarditis, which partly explains the
relatively low incidence of this disease.
From the seminal studies performed in animal models, it
has been well known that inducing infective endocarditis in
the absence of pre-existing endothelial damage is extremely
difficult (34, 35). Important predisposing conditions are prior
valvular involvement, classically rheumatic or currently due
to degenerative disease (as well as the presence of prostheses
or endovascular devices). These structural alterations induce
turbulent blood flow that causesmechanical stress on the vascular
wall, ultimately producing endothelial injury. More recently,
the ability to induce experimental endocarditis in structurally
healthy, but inflamed valves has been demonstrated (36). This
mechanism could explain the development of endocarditis in
previously normal hearts in patients with infections caused by
aggressive microorganisms (e.g., S. aureus) and with endothelial
inflammation caused by sepsis itself or by other agents that cause
vascular damage.
After the initial endothelial damage or inflammation, the
second key pathogenic event is the deposition of sterile fibrin-
platelet aggregates in these injured areas. These lesions, leading
to what is known as “non-bacterial thrombotic endocarditis,”
have been described in up to 2.4% of the autopsies performed
in patients with certain underlying diseases (37) and are the
ideal niche for the subsequent anchoring of the bacteria seeded
in the bloodstream. Not all bacteria from the bloodstream,
however, have the same ability to colonize these lesions (38).
Gram-negative bacilli, for example, are particularly susceptible
to humoral innate immune responses (39). Furthermore, certain
Gram-positive microorganisms, particularly some species of
streptococci and S. aureus, have specific molecules on their
surfaces called adhesins, such as “microbial surface components
recognizing adhesive matrix molecules” (MSCRAMMs) and
“secretable expanded repertoire adhesive molecules” (SERAMs).
These adhesins recognize integrins, specific ligands located on
the injured or inflamed endothelial surface. Since the 1980s to
1990s, a repertoire of molecules of the MSCRAMM and SERAM
type have been described in detail for streptococci and S. aureus
(40–44), which interact not only with the endothelium, but also
with platelets and key proteins of the clotting cascade (45–47).
The last important pathogenic event is the maturation and
growth of the fibrin-platelet aggregates, which clump together
with bacteria at a high inoculum (more than 109 colony-
forming units per gram of vegetation) in what is known as
“vegetation.” Within this vegetation, bacterial communities are
partly organized into complex biofilms, embedded in the fibrin-
platelet aggregate and in a matrix of macromolecules produced
by them. The arrival of phagocytes and antibiotics can be
compromised in these structures, inside which bacteria can
also modify their metabolism toward persistent phenotypes,
with greater tolerance to antibiotics (48–50). The vegetation
represents the pathological hallmark of infective endocarditis
and determines its main clinical manifestations, namely: (1)
the growth of this “full bacterial lesion” causes continuous
bacteremia at a high inoculum that can seed distant septic
metastases, (2) the invasion of the structures to which this
vegetation is anchored can cause valvular destruction, negatively
affecting the patient’s hemodynamics, and finally (3) this friable
mass can detach pieces that cause distant embolisms, which
can significantly affect the function and prognosis of the
affected patients. In recent years, intensive studies have been
carried out in this field. Through pharmacological manipulation,
successful attempts have been made to hinder the interactions
between bacteria and the endothelium, effectively preventing the
development or modulating the severity of infective endocarditis
in animal models treated with antiplatelet and anticoagulant
drugs (51, 52). Although the possible prophylactic role of
some antiplatelet or anticoagulant drugs has been reinforced by
observational clinical studies (53–55), the prophylactic use of
these drugs has not been effectively transferred to clinical practice
yet (56).
Endocarditis-Triggered Sepsis and Septic
Shock
As described previously, a non-negligible proportion of
patients with endocarditis may present with severe sepsis or
septic shock (28), which can eventually lead to multi-organ
failure. This complication appears to be associated with some
characteristics of the patients (57) as well as with particularly
virulent microorganisms such as S. aureus and beta-hemolytic
streptococci (58). In addition to their invasive and destructive
effects on the affected anatomical structures, these bacteria can
seed distant septic metastases. Moreover, they display a repertoire
of other virulence mechanisms, including the excretion of
exotoxins that can act as superantigens, which overactivate the
immune system (59–61). The systemic inflammation that is
consequently triggered has an important hemodynamic impact,
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with generalized endothelial dysfunction and a drop in vascular
resistance. Any increases in the compensatory cardiac output
may be hampered by sepsis itself, a phenomenon known as
“septic cardiomyopathy” (62), or by the destruction of the valve
as a result of the infection. This extremely serious situation
explains why the presence of septic shock is associated with a
significant increase in the risk of mortality.
DIAGNOSTIC TOOLS
The diagnosis of infective endocarditis relies on a combination
of clinical, microbiological and imaging information, as specified
by themodified Duke criteria (63, 64). The classic combination of
clinical features of infective endocarditis remains a critical feature
in diagnosis, particularly for subacute or chronic endocarditis.
The mainstay of diagnosis involves the information provided
by blood cultures and different imaging techniques that can
detect anatomical changes such as valve vegetations or associated
complications. However, a shift toward more acute infections
and the involvement of prosthetic materials have decreased, to
some extent, the usefulness of applying these classic clinical
features in diagnosis. The performance of the modified Duke
criteria has been thus compromised in the era of non-community
acquired infective endocarditis. Therefore, modifications have
been proposed to improve their sensitivity (65, 66). Nowadays,
the diagnostic accuracy of these criteria seems to largely rely on
the development of new andmore sensitive non-invasive imaging
techniques (Table 1).
Echocardiography
Transthoracic echocardiography (TTE) is the main imaging
method in the diagnosis of endocarditis, with varying sensitivity
rates for valvular and paravalvular abnormalities such as
vegetations (sensitivity around 65%), a new regurgitation or
dehiscence of a prosthetic valve, perforations, abscesses and
fistulae (64). Transesophageal echocardiography (TOE) provides
a better detection and characterization of local abnormalities
(sensitivity for intracardiac vegetations of ∼95%), particularly
when TTE is negative, in the case of valvular or paravalvular
complications as well as in prosthetic valve endocarditis (PVE)
and endocarditis associated with CIEDs (67).
Three-dimensional TOE (3D-TOE) may complement
conventional TOE. Although its contribution to the diagnosis
of endocarditis is not clearly established (68, 69), its main
value is in providing a detailed description of vegetations,
regurgitations and abscesses in both native (70) and prosthetic
valve endocarditis (71). This technique can also differentiate
vegetations from thrombi (72) and can be used in surgical
planning. Intraoperative TOE has been demonstrated to be
useful in the surgeries for endocarditis and has been proposed
for use in routine exploration (73, 74).
Cardiac Computed Tomography
Although TOE remains the mainstay in the diagnosis of infective
endocarditis, there is growing interest in the application of
cardiac computed tomography (CT). This tool shows good
anatomical correlation, especially when diagnosing a perivalvular
abscess of the aortomitral intervalvular fibrous body and other
structures surrounding the aortic root, thus overcoming the
limitations of TOE (75–77). Recent data support cardiac CT
as an adjuvant exploration technique when a better depiction
of valvular complications is needed or when echocardiography
proves to be insufficient in both native (77) and prosthetic valve
endocarditis (78–80). Furthermore, cardiac CT is frequently
used to preoperatively assess the presence of coronary artery
disease in aortic endocarditis where performing a coronary
angiography carries a prohibitive high risk of the dislodgment
of vegetations (74). A recent study from Wang and colleagues
added a prognostic value to cardiac CT, suggesting a synergistic




To complement the detection of anatomic abnormalities,
progress has been made in measuring biological activity
through 18F-fluorodeoxyglucose positron emission/computed
tomography (FDG-PET/CT) and radiolabeled white blood cell
single-photon emission CT/CT (WBC-SPECT/CT). Their use
has been recommended by the European Society of Cardiology
in patients with suspected PVE for valves implanted for more
than 3 months (74), with a positive result included as a major
criterion for the diagnosis of prosthetic valve and device-related
endocarditis. Prospective studies of patients with suspected PVE
have revealed a remarkable performance of FDG-PET/CT and
WBC-SPECT/CT in the diagnosis of PVE (82, 83). They suggest
that these two imaging techniques can be used in a stepwise
fashion when evaluating the presence of endocarditis. FDG-
PET/CT should be used first, since it has higher sensitivity, and
when the results are not conclusive, WBC-SPECT/CT may be
performed. Similar results have been obtained with both FDG-
PET/CT (84, 85) and WBC-SPECT/CT (86–89) for suspected
CIEDs endocarditis. Controversy remains on the use of FDG-
PET/CT in patients with aortic root grafts with a prosthetic valve,
since a high rate of false positives has been observed in relation to
surgical adhesives (82, 90). FDG-PET/CT performs very well in
the diagnosis of PVE when adjusting for confounders such as the
low inflammatory activity caused by the initiation of antibiotic
treatment (82, 90, 91), suggesting that FDG-PET/CT should be
performed as soon as possible when infective endocarditis is
suspected. Furthermore, FDG-PET/CT has proven prognostic
value in PVE by correlating with major cardiac events (92).
The role of FDG-PET/CT in the diagnosis of native valve
endocarditis has not been fully established and may be limited
to cases where endocarditis is strongly suspected but the Duke
criteria are not totally met. Studies on the use of FDG-PET/CT
in native valve endocarditis are mostly retrospective and might
overestimate the sensitivity of this technique (93, 94). In such
cases, FDG-PET/CT may have an impact on diagnosis by
detecting extracardiac complications of endocarditis (95).
The increasing use of TAVI and left ventricular assist devices
(LVAD) have led to challenges in diagnosing the infective
complications associated with their use. A recent study in
Frontiers in Medicine | www.frontiersin.org 4 February 2021 | Volume 8 | Article 641243
Cuervo et al. Challenges in Infective Endocarditis
TABLE 1 | Imaging and laboratory techniques used in the diagnosis of infective endocarditis.
Transthoracic echocardiography (TTE) Mainstay of diagnosis.
Limited sensitivity in prosthetic valve endocarditis and paravalvular complications.
Transesophageal echocardiography (TOE) Mainstay of diagnosis.




Complement to TOE when characterizing valvular and paravalvular complications.
Surgical planning
Intraoperative transesophageal echocardiography Routine exploration when surgery is performed. Assessment of post-operative anatomy and ventricular
function.
Cardiac computed tomography (CT) Better characterization of complications involving an aortomitral fibrous body and the aortic root.
Alternative to coronary angiography for exploration in patients with aortic endocarditis.
Positron emission tomography/computed tomography
(PET/CT)
Major Duke criteria for diagnosis of prosthetic valve endocarditis and device-associated endocarditis.
Increasing use in infective endocarditis associated with TAVI and LVAD.
Detection of extracardiac complications of endocarditis or alternative sources of infection.
Radiolabeled white blood cell single-photon emission
computed tomography/computed tomography
(WBC-SPECT/CT)
Complement to PET/CT when results are non-conclusive.
Similar performance to that of PET/CT.
Brain magnetic resonance imaging (MRI) Detection and characterization of silent or clinically evident intracranial complications.
Evaluation of evolving changes in intracranial complications that may influence the timing for surgery.
Thoracoabdominopelvic computed tomography Not recommended as a routine exploration in asymptomatic patients.
Contrast-enhanced ultrasound Promising results on detecting intraabdominal emboli as an alternative to CT.
Colonoscopy Detection of colorectal disease or neoplastic processes in Streptococcus gallolyticus or Enterococcus faecalis
endocarditis.
Culture and polymerase chain reaction of samples from
explanted heart valves
Improves the diagnostic performance of the Duke criteria.
Serum cytokine profiles and bacteria-targeting tracers Under research; not routinely used.
TAVI, transcatheter aortic valve implantation; LVAD, left-ventricle assistance devices.
patients with suspected TAVI-related endocarditis showed that
the inclusion of FDG-PET/CT led to the reclassification of
36% of the patients diagnosed with “possible endocarditis”
by the modified Duke criteria (96). Moreover, FGD-PET/CT
and WBC-SPECT/CT have been used in cases of endocarditis
associated with LVADs, showing variable rates of sensitivity and
specificity (97–100). WBC-SPECT/CT and FDG-PET/CT show
similar sensitivity and specificity, but the former may be more
challenging to perform since it uses a more difficult protocol and
requires the manipulation of blood specimens.
FDG-PET/CT is also useful in revealing unexpected
sources of primary infections and detecting extracardiac
complications of endocarditis. Thus, its use can lead to changes
in treatment plans (101). However, no recommendations have
been made in international guidelines regarding the detection of
extracardiac complications.
Cerebral Imaging
Recommendations for neuroimaging in infective endocarditis
remain unclear. Brain CT is often used when neurological
symptoms are present, although brain magnetic resonance
imaging (MRI) has better sensitivity in defining lesions. Clinically
silent complications of the central nervous system, such as
embolisms, may occur in up to 60% of patients (102).
Some centers routinely perform brain MRI when infective
endocarditis is diagnosed since it may provide additional
diagnostic findings for fulfilling the modified Duke criteria
and may change therapeutic plans (103) or the timing for
surgery (104). However, while major intracranial hemorrhages
and extensive ischemic stroke worsen prognosis after valve
surgery, brain MRI findings of clinically silent complications
do not affect postoperative mortality (105). In this sense, the
clinical significance of cerebral microbleeds, one of the most
frequently encountered silent lesions, remains to be elucidated
(106, 107).
Other Diagnostic Tools
Systematic thoracoabdominopelvic CT has not demonstrated
a clear utility in the diagnosis of left-sided endocarditis in
asymptomatic patients. Furthermore, it increases the risk of
kidney toxicity (108). Nevertheless, the finding of pulmonary
embolisms in chest CT may be useful in the diagnostic workup
of right-sided endocarditis either on the tricuspid native valve in
intravenous drug addicts or associated with pacemakers (109).
Contrast-enhanced ultrasound may be useful as an alternative
for the detection of abdominal complications, mostly spleen
infarctions (110).
Regarding the detection of the portals of bacterial entry,
colonoscopy has proved to be very useful. The relationship
between Streptococcus gallolyticus and colon cancer has been
well known since the 1950s (111). Two observational studies
on infective endocarditis caused by Enterococcus faecalis
found a high rate of colorectal disease when a colonoscopy
was performed, with a high incidence of neoplastic disease
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particularly in those with an unknown source of bacteremia
(112, 113). A systematic and multidisciplinary search for portals
of bacterial entry has been proposed, suggesting that a meticulous
physical examination should be performed when evaluating
patients with infective endocarditis (114).
Procedures involving polymerase chain reaction (PCR) using
samples from explanted heart valves could improve diagnostic
performance (115) in comparison with conventional cultures.
Although interesting from a theoretical point of view, those
molecular techniques applied to the detection of genetic material
in blood samples for cases of culture-negative endocarditis have
shown low sensitivity so far (116). Finally, there is an increasing
interest in finding new predictors of mortality in patients
with endocarditis through the use of serum cytokine profiles
(117) or bacteria-targeting tracers alongside diverse nuclear
imaging techniques (118). Regarding acute-phase reactants
and biomarkers of severe infection, procalcitonin levels are
significantly increased in the cases of endocarditis complicated
with sepsis or septic shock when compared to cases without
these complications (119). No other biomarker has demonstrated
a good predictive value in this setting. Current research of
biomarkers in endocarditis is focused on proteomic analysis of
some molecules that are not yet in routine clinical use (120).
To conclude, progress has been made through the
development of new diagnostic techniques and improvements
in known ones. However, for a complex and systemic disease
such as infective endocarditis, it seems that diagnosis will be
further improved by using a refined combination of clinical,
microbiological and multimodal imaging information.
MANAGEMENT
The available evidence to guide antibiotic treatment of infective
endocarditis is composed mostly of data from observational
studies and some from experimental animal models. A recent
Cochrane review analyzed the evidence from six small clinical
trials evaluating various antibiotic regimens for endocarditis with
a range of etiologies. After an in-depth analysis, the authors of the
review concluded that given the high risk of bias, insufficient data,
or underpowered designs, the evidence offered by these trials did
not support or reject any of the regimens evaluated (121). This
poor evidence may partly explain the significant heterogeneity
in the management of this disease observed in some surveys
(122) and the lack of adherence to some recommendations
of the European guidelines even among those who developed
them (123).
With these caveats in mind, when treating this infection, the
pathophysiological peculiarities of infective endocarditis must
be taken into account, such as the presence of very high
concentrations of bacteria protected from immune responses
within vegetations and the potential existence of bacteria with
reduced metabolism embedded in biofilms. For these reasons, it
has been postulated that to achieve microbiological eradication,
the treatment of infective endocarditis must involve bactericidal
antibiotics administered parenterally in high doses and for
prolonged periods (124).
The selection of the antibiotic regimen for a particular case
of endocarditis is often complex and beyond the scope of this
review. All the details on this are available in the published
guidelines (74, 125). However, in the next few paragraphs,
we will offer a brief overview of the common regimens that
are used against the most frequent microorganisms that cause
infective endocarditis.
Antibiotic Therapy
Cell Wall-Active Antibiotic Treatment
The cornerstone of the antibiotic treatment of endocarditis
is the use of beta-lactams in high doses: penicillin or
ceftriaxone for the viridans group streptococci, ampicillin for
E. faecalis, and antistaphylococcal penicillins or first-generation
cephalosporins for methicillin-sensitive S. aureus or coagulase-
negative staphylococci. In allergic patients or in those with
infections caused by strains resistant to beta-lactams, the
alternative is usually another cell wall-active agent, such as
vancomycin for the viridans group streptococci and E. faecalis or
vancomycin or daptomycin for staphylococci. Due to the limited
amount of evidence, treatment regimens for endocarditis caused
by coagulase-negative staphylococci are usually extrapolated
from those recommended for treating endocarditis caused by
S. aureus (126).
Antibiotic Combinations
The synergistic combination of aminoglycosides and beta-
lactams demonstrates rapid bactericidal action, allowing
treatment to be shortened to 2 weeks for native valve endocarditis
caused by susceptible viridans group streptococci (127). This
antibiotic combination is also recommended for treating
infections caused by the viridans group streptococci that
are partially or fully resistant to penicillin, although this
recommendation is based on less robust evidence (128, 129).
The combination of ampicillin and aminoglycosides is
essential for at least the first 2 weeks of treatment (130) to
reduce the risk of relapse in endocarditis caused by E. faecalis,
given the relative tolerance of these bacteria to beta-lactams
(which is also observed in other species such as Granulicatella
adiacens and Abiotrophia defectiva). When this combination
cannot be used due to high-level aminoglycoside resistance or an
unacceptable risk of toxicity, combination with ceftriaxone (so-
called “double beta-lactam”) is recommended, which achieves
bactericidal action presumably through the complementary
saturation of penicillin-binding proteins (PBPs) (131, 132).
In endocarditis caused by S. aureus, the combination of beta-
lactams and aminoglycosides is currently not recommended
for native valve infections due to the increased risk of renal
toxicity without any relevant clinical benefit (133, 134). It is only
recommended for PVE according to experimental data, although
some retrospective series question its usefulness even in that
scenario (135).
The use of rifampicin in a combination treatment for native
valve endocarditis caused by S. aureus is discouraged (136), but
could be useful in PVE, given its potent activity in infections
involving biofilms. Guidelines recommend this regimen for PVE,
but only after clearing blood cultures to avoid the emergence of
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resistant mutants during treatment (136). In any case, this drug
may not be essential after valve replacement surgery in patients
operated during the active phase of treatment (137).
There is enormous interest in the potential utility of the
combination of beta-lactams with daptomycin or fosfomycin
in endocarditis caused by methicillin-susceptible S. aureus.
Experimental evidence shows that combinations of both drugs
with cloxacillin produce greater sterilization of vegetations on
the left-sided valves in animal models (138). However, this
potential beneficial effect of the combination with daptomycin
was not observed in a retrospective study conducted in our
center (139) or in a recent clinical trial of bacteremia caused
by susceptible S. aureus (140), although it is worth mentioning
that there was an underrepresentation of infective endocarditis
as a cause of bacteremia in both studies (9 and 10% of patients,
respectively). The combination of cloxacillin with fosfomycin
in bacteremia and endocarditis caused by susceptible S. aureus
is an attractive alternative. In an ongoing multicenter clinical
trial (SAFO trial) we are testing this combination for bacteremia
caused by methicillin-susceptible S. aureus (141).
In the case of endocarditis caused by methicillin-resistant
S. aureus (MRSA), combination therapy is likely to be more
effective given the relatively poor results of both vancomycin
and daptomycin monotherapy. The possible synergistic effect of
vancomycin and beta-lactams in MRSA bacteremia suggested by
in vitro studies, retrospective studies (142, 143) and a pilot clinical
trial (144) could not be confirmed in the international multi-
center CAMERA 2 clinical trial. This trial had to be prematurely
discontinued due to greater renal toxicity in the combination
arm, which was associated with a shorter duration of bacteremia,
but no differences in mortality between the groups (145).
The combination of daptomycin and fosfomycin has
produced promising results in animal models of MRSA
endocarditis (146). This combination has also shown good
microbiological results and clinical benefits in patients aged
under 70 years in our recent clinical trial of MRSA bacteremia
(BACSARM trial) (147), which again had a poor representation
of endocarditis cases (diagnosed in 12% of the cases).
Finally, combinations of daptomycin and beta-lactams
without and with intrinsic anti-MRSA activity for the treatment
of MRSA bacteremia have been shown to be effective in
a retrospective study (148) and in a pilot clinical trial
(149), respectively, although with little specific information for
endocarditis cases.
Length of Antibiotic Therapy
Even in infections caused by susceptible microorganisms, the
risk of microbiological relapse is plausible in endocarditis.
For this reason, long treatments are typically recommended,
generally 4 weeks for native valve endocarditis and 6 weeks
for PVE. Exceptions to this general rule are the abbreviated
2-week treatments that have proved to be effective for right-
sided endocarditis (150) and the combination treatment of
beta-lactams and aminoglycosides for native valve endocarditis
caused by penicillin-susceptible viridans group streptococci
(127). Furthermore, there are clinical trials currently underway
that aim to demonstrate the efficacy of shorter-than-standard
therapeutic regimens (151).
In native valve endocarditis caused by E. faecalis, 4-week
aminoglycoside treatment courses are recommended for cases
with a clinical evolution shorter than 3 months (152). In cases
with a longer symptomatic duration and in those using the
double beta-lactam combination, a 6-week treatment course is
recommended (153).
The decision of the total duration of antibiotic therapy in
patients undergoing surgery during the active phase of treatment
is affected by the result of the valve culture (154). According
to the findings of a retrospective study, an antibiotic treatment
duration of 2 weeks after surgery may be sufficient for valve
culture-negative streptococcal endocarditis (155). Management
guidelines recommend completing the pre-stipulated duration of
the antibiotic treatment course when the valve culture is negative
and, conversely, restarting a complete cycle if the valve is not
sterile at the time of surgery.
Outpatient Parenteral Antibiotic Treatment
Infective endocarditis requires long and expensive
hospitalizations for its management given the need to administer
parenteral antibiotics for several weeks. Outpatient parenteral
antibiotic treatment (OPAT) has been shown to be efficient
and cost-effective in the management of endocarditis. A series
of specific criteria must be met by the patients for them to
be considered safe candidates for OPAT (156). Generally, this
option is considered suitable for patients who have overcome the
critical phase of the disease (first 2 weeks), provided that they
remain stable. Recent studies have demonstrated the safety of
this strategy, even expanding the restrictive criteria proposed in
the guidelines (157).
New Antibiotic Molecules
In recent years, new antibiotics targeting Gram-positive
microorganisms (and, therefore, potentially useful for
treating endocarditis) have been incorporated. The fifth-
generation cephalosporins ceftaroline and ceftobiprole
represent the first beta-lactams with intrinsic anti-MRSA
activity. Although infective endocarditis is not among the
approved indications based on pivotal clinical trials, there
are case series that have reported that its off-label use is
an effective salvage treatment in patients with endocarditis
(158, 159). Ceftaroline and, in particular, ceftobiprole also
have anti-enterococcal activity (160), which makes them
attractive as candidates for combination treatments with
ampicillin or daptomycin in managing enterococcal infective
endocarditis (161).
Another interesting new molecule is the lipoglycopeptide
dalbavancin, a bactericidal drug with a chemical structure and
antibacterial spectrum similar to those of teicoplanin, but with
a very long half-life that allows its administration every week
or every 2 weeks. Dalbavancin is a potentially useful option for
OPAT in selected patients. In vitro studies have demonstrated
its potent activity against endocarditis-producing strains (162).
Furthermore, recently published series of cases indicate that it
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shows efficacy as a continuation drug in endocarditis cases of
diverse etiology (163, 164).
Oral Antibiotic Treatment
The effectiveness of oral treatment for endocarditis has been
demonstrated for cases involving right-sided valves (165), as
stated in the management guidelines. For left-sided endocarditis,
retrospective studies (166), a small clinical trial of endocarditis
caused by the viridans group streptococci (167) and a recent
randomized clinical trial (168) of endocarditis with diverse
etiologies (streptococci, enterococci, and staphylococci) have
demonstrated that partial oral regimens are effective in treating
selected patients who have overcome the critical phase.
In that recent randomized clinical trial, the POET trial, 1,954
patients were evaluated, of whom 400 were finally selected. After
a minimum of 10 days of intravenous antibiotic therapy, the
patients were randomized to continue intravenous therapy or to
complete treatment with a combination of oral drugs. The clinical
endpoint was a composite of all-cause mortality, unplanned
cardiac surgery, embolic events, and relapse of bacteremia with
the primary pathogen from the time of randomization until
6 months after the completion of antibiotic treatment. This
endpoint was found to be similar between the groups. Due
to the diverse etiologies included in the trial and the various
combinations of oral antibiotics administered, the results of
the POET trial cannot be used to make specific therapeutic
recommendations. However, this trial has raised the possibility
of including oral sequential treatment as a suitable option for
treatment completion in selected patients.
Antimicrobial Treatment for Fungal and
Culture-Negative Endocarditis
Antifungal treatment for Candida spp. endocarditis is usually
based on the use of drugs with fungicidal activity, either based
on regimens with liposomal amphotericin B (or other lipid
formulations) with or without flucytosine or on regimens based
on echinocandins in high doses. Although the evidence is scarce,
based mostly on retrospective experiences and expert consensus,
the use of combined treatments and long-term azole suppressive
treatments is frequent. A high number of cases will require
surgical intervention as part of the management (169). On the
other hand, in the rare cases of endocarditis due to Aspergillus
species (often responsible for culture-negative endocarditis), the
most commonly used antifungal is voriconazole and the surgery
requirements is also high (74, 125).
The appropriate selection of an empirical antibiotic treatment
for patients with culture-negative endocarditis is a difficult
task and so expert consultation is recommended. The decision
is often conditioned by the clinical presentation of the
disease, the presence or absence of prosthetic material and
other epidemiological data such as other comorbidities, dental
hygiene, alcoholism, contact with animals, etc. Thus, for
patients with native valves and subacute presentation, empirical
treatment should cover viridans group streptococci, enterococci
and HACEK (e.g., ampicillin plus either gentamicin or
ceftriaxone) whereas in cases with acute clinical presentation
and/or presence of prosthetic valves it seems reasonable to
cover Staphylococcus aureus, coagulase-negative staphylococci,
β-hemolytic streptococci and aerobic gram-negative bacilli
(e.g., cloxacillin plus ceftriaxone plus either vancomycin or
daptomycin) (170, 171) The details on directed treatment options
for specific pathogens are available in the published guidelines
(74, 125).
Surgical Treatment
More than 50% of patients with endocarditis will need valve
surgery. Among these, a significant proportion will require it
during the active phase (that is, during the initial hospitalization
and before the end of antibiotic treatment), which is known
as early valve surgery (EVS). Although both the American
and European guidelines have the same indications for EVS
(Table 2) (74, 125), the latter guideline goes further in terms
of recommending the timing of surgery. It suggests emergent
surgery (within the first 24–48 h) in the case of refractory heart
failure secondary to valve regurgitation, and an urgent surgery
(during the first week) in almost all other clinical settings.
This contentious issue of the timing of surgery in the
guidelines is partly due to the limited and conflicting evidence
published to date that is difficult to interpret. There is only one
randomized clinical trial that has demonstrated a clinical benefit
in terms of a reduction in embolic events for “very” EVS in
young patients (median age of 48 years) with native mitral valve
endocarditis and mostly caused by streptococcal bacteria (172).
It is unclear to what extent this evidence can be extrapolated to
older patients and to endocarditis with other etiologies.
Most of the available evidence consists of findings from
retrospective studies that require laborious statistical adjustments
in order to mitigate indication and survival biases and draw valid
conclusions. According to these studies, the benefit of EVS can
only be demonstrated for native valve endocarditis with surgical
requirement (173). The benefit is less evident in the case of PVE
(only demonstrated in patients who are more likely to require
surgery) (174) and could be present in some carefully selected
patients with PVE caused by S. aureus (175).
It seems reasonable to conclude that the decision to proceed
with an emergency or urgent valve surgery during the active
phase of endocarditis cannot be recommended systematically
TABLE 2 | Indications for surgery in left-sided valve endocarditis (74).
Heart failure
• Severe acute regurgitation, obstruction or fistula causing refractory
pulmonary edema or cardiogenic shock.
Uncontrolled infection
• Locally uncontrolled infection (abscess, false aneurysm, fistula, or enlarging
vegetation).
• Persistent positive blood cultures despite appropriate antibiotic therapy.
• Infection caused by fungi or multidrug-resistant organisms or prosthetic valve
endocarditis caused by staphylococci or non-HACEK
Gram-negative bacteria.
Prevention of embolism
• Persistent vegetations >10mm after one or more embolic episode despite
appropriate antibiotic therapy or severe valve stenosis or regurgitation.
• Isolated very large vegetations (>30mm).
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FIGURE 1 | Management of infective endocarditis.
or routinely. Instead, this decision should be based on an
individualized assessment (176).
Management of Sepsis in Endocarditis
The management of septic shock in patients with endocarditis
does not seem to differ from that recommended for sepsis from
other sources (59). In addition to volume expansion, vasoactive
drugs in some cases and the early initiation of appropriate
bactericidal antibiotic treatment, there is still no clinical evidence
about the possible effectiveness of additional immunomodulatory
treatments in cases of endocarditis and suspected toxic shock
(61). It seems appropriate to point out that early valve surgery
may be necessary in some cases as a source control measure
(30), such as in cases with uncontrolled infection despite correct
antibiotic treatment.
CONCLUSIONS AND PERSPECTIVE
It is evident that the management of infective endocarditis
requires the close collaboration of a multidisciplinary team
that includes experts in critical care for patients with severe
sepsis or septic shock. The training of endocarditis teams
is recommended by the guidelines, while some studies have
demonstrated the beneficial impact of their performance on
patient outcomes (177, 178).
It seems reasonable to conclude that patients with endocarditis
should be evaluated preferentially by these multidisciplinary
teams in the critical phase of the disease, at which time the
most appropriate initial intravenous antibiotic therapy should
be chosen. New therapeutics and possible new synergistic
combinations of antibiotics are of very high interest. After a
thorough clinical and anatomical cardiac evaluation, patients
eligible for surgical treatment should be selected and the
timing of the intervention decided. It is possible that in
coming years, an increasing proportion of appropriately
selected patients will be able to continue their antibiotic
treatment in home hospitalization regimens with OPAT, using
long half-life parenteral antibiotics or combinations of oral
antibiotics (Figure 1).
There is a need for international and multi-center working
groups to establish a common work agenda in order to
scientifically address all the unresolved diagnostic and
therapeutic aspects of infective endocarditis.
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